Reviewing RXi Pharmaceuticals Corporation (RXII) & Alnylam Pharmaceuticals (ALNY)
RXi Pharmaceuticals Corporation (NASDAQ: RXII) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
This table compares RXi Pharmaceuticals Corporation and Alnylam Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RXi Pharmaceuticals Corporation||N/A||-155.48%||-102.55%|
This is a summary of current ratings and recommmendations for RXi Pharmaceuticals Corporation and Alnylam Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RXi Pharmaceuticals Corporation||0||0||0||0||N/A|
RXi Pharmaceuticals Corporation presently has a consensus target price of $1.71, indicating a potential upside of 222.64%. Alnylam Pharmaceuticals has a consensus target price of $85.50, indicating a potential upside of 6.05%. Given RXi Pharmaceuticals Corporation’s higher possible upside, research analysts plainly believe RXi Pharmaceuticals Corporation is more favorable than Alnylam Pharmaceuticals.
Insider & Institutional Ownership
1.7% of RXi Pharmaceuticals Corporation shares are held by institutional investors. Comparatively, 94.3% of Alnylam Pharmaceuticals shares are held by institutional investors. 5.7% of RXi Pharmaceuticals Corporation shares are held by insiders. Comparatively, 4.3% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
RXi Pharmaceuticals Corporation has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500.
Valuation & Earnings
This table compares RXi Pharmaceuticals Corporation and Alnylam Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|RXi Pharmaceuticals Corporation||N/A||N/A||-$9.40 million||($1.32)||-0.40|
|Alnylam Pharmaceuticals||$66.00 million||112.05||-$436.51 million||($5.12)||-15.75|
RXi Pharmaceuticals Corporation has higher revenue, but lower earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals Corporation, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals beats RXi Pharmaceuticals Corporation on 6 of the 11 factors compared between the two stocks.
RXi Pharmaceuticals Corporation Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.